We conclude that MIF contributes to the hypoxic pulmonary hypertension, but further studies will be needed to extend these findings, with the aim of identifying new therapeutic targets for treatment of pulmonary hypertension. The gene discussed is MIF; the disease is pulmonary arterial hypertension.